title: Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients.
abstract: OBJECTIVE
  The ALK inhibitor, crizotinib, has demonstrated effectiveness in patients with non-small-cell lung cancer harboring ALK rearrangements. As few studies of the clinical characteristics of Chinese patients with ALK rearrangements have been reported, we conduct this study to gain more understanding in such area among Chinese patients.
  
  
  METHODS
  We undertook a retrospective study of 288 non-small-cell lung cancer patients admitted to our institution over a period of 4.5 years.
  
  
  RESULTS
  Following testing, 14.9% of the patients (43/288) were found to be ALK fusion gene positive. Patient data including gender, age, smoking status, EGFR mutation status and medical imaging data were collected and analyzed.
  
  
  CONCLUSIONS
  The findings suggested that patients with ALK rearrangements are more likely to be young, have EGFR wild-type, and more likely to exhibit mucus secretion, solid tumor growth, lymph node metastasis and pleural metastasis.
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Guangming
authors.initials: G
authors.lastname: Tian
authors.affiliation: Department of Medical Genetics, Peking University Health Science Center, Beijing, China.
authors.forename: Xinliang
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Nie
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Dai
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Weiheng
authors.initials: W
authors.lastname: Hu
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Jindi
authors.initials: J
authors.lastname: Han
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Xiangjuan
authors.initials: X
authors.lastname: Ma
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Di
authors.initials: D
authors.lastname: Wu
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Sen
authors.initials: S
authors.lastname: Han
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Jieran
authors.initials: J
authors.lastname: Long
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Thoracic Oncology II, Peking University Cancer Hospital & Institute, Beijing, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Fang
mesh_terms: D000328:Adult; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D044466:Asian People / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology*; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D016133:Polymerase Chain Reaction; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D015514:Oncogene Proteins, Fusion; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK rearrangements; adenocarcinoma; gene mutations; non-small-cell lung cancer